Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Diuretics for cardiovascular prevention in the elderly

Journal of Human Hypertension volume 18, pages S15–S22 (2004)Cite this article

Abstract

High blood pressure (BP) is a major risk factor for cardiovascular and cerebrovascular diseases in elderly subjects. Antihypertensive drugs have shown clinical benefit both in primary and secondary prevention of cardiovascular events. If BP lowering represents the major determinant of the effects conferred by the antihypertensive treatment for prevention, recent studies have suggested some differences between classes of antihypertensive drugs according to age. Based on the available clinical data, the recent medical guidelines have recommended thiazide-type diuretics as the preferred drug for the treatment of elderly hypertensive patients, followed by long-acting calcium antagonists. Indeed, diuretics constitute one of the most valuable classes of antihypertensive drugs, and in the elderly, diuretic-based treatment studies have been clearly shown to prevent major cardiovascular events, including stroke, heart failure and coronary heart disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Burt VL et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995; 25: 305–313, 444.

    CAS  Google Scholar 

  2. Burt VL et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 1995; 26: 60–69.

    Article  CAS  Google Scholar 

  3. Chobanian AV, et al, the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.

    Article  CAS  Google Scholar 

  4. Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.

  5. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983–1992.

  6. Staessen JA et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865–872.

    Article  CAS  Google Scholar 

  7. Morgan TO et al. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens 2001; 14: 241–247.

    Article  CAS  Google Scholar 

  8. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405–412.

  9. Dalohf B et al. Morbidity and mortality in the Swedish Trial in Old Patients with hypertension (STOP Hypertension). Lancet 1991; 338: 1281–1285.

    Article  Google Scholar 

  10. Ekbom T et al. Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOP-Hypertension study. J Hypertens 1992; 10: 1525–1530.

    Article  CAS  Google Scholar 

  11. Messerli FH, Grossman E, Goldbourt U . Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279: 1903–1907.

    Article  CAS  Google Scholar 

  12. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–2997.

  13. Weinberger MH . Salt sensitivity of blood pressure in humans. Hypertension 1996; 27: 481–490.

    Article  CAS  Google Scholar 

  14. Messerli FH et al. Essential hypertension in the elderly: haemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels. Lancet 1983; 2: 983–986.

    Article  CAS  Google Scholar 

  15. Amery A et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial. Lancet 1985; 1: 1349–1354.

    Article  CAS  Google Scholar 

  16. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–3264.

  17. Brown MJ et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–372.

    Article  CAS  Google Scholar 

  18. Black HR et al. Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial. JAMA 2003; 289: 2073–2082.

    Article  CAS  Google Scholar 

  19. Hansson L et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751–1756.

    Article  CAS  Google Scholar 

  20. Hansson L et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359–365.

    Article  CAS  Google Scholar 

  21. Wing LM, et al, Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting—enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583–592.

    Article  CAS  Google Scholar 

  22. Bulpitt CJ, et al, On behalf of the Hypertension in the Very Elderly Trial (HYVET) Working Group. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003; 21: 2409–2417.

    Article  CAS  Google Scholar 

  23. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283: 1967–1975.

  24. Psaty BM et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289: 2534–2544.

    Article  CAS  Google Scholar 

  25. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–1041.

  26. Tzourio C, et al, PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163: 1069–1075.

    Article  CAS  Google Scholar 

  27. Dahlof B, et al, LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.

    Article  CAS  Google Scholar 

  28. Kjeldsen SE, et al, LIFE (Losartan Intervention for Endpoint Reduction) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002; 288: 1491–1498.

    Article  CAS  Google Scholar 

  29. Lithell H, et al, SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–886.

    Article  CAS  Google Scholar 

  30. Pepine CJ, et al, INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil–Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805–2816.

    Article  CAS  Google Scholar 

  31. Julius S, et al, VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–2031.

    Article  CAS  Google Scholar 

  32. Gueyffier F et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet 1999; 353: 793–796.

    Article  CAS  Google Scholar 

  33. Bulpitt C et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs Aging 2001; 18: 151–164.

    Article  CAS  Google Scholar 

  34. Van de Ven LLM . Age-dependent differences in the efficacy and tolerability of different classes of antihypertensive drugs. Clin Drug Invest 1997; 14: 16–22.

    Article  CAS  Google Scholar 

  35. Marre M et al. The extent of microalbuminuria reduction with indapamide SR in elderly hypertensive type 2 diabetic patients: the Nestor study. J Hypertens 2003; 21(Suppl 4): S183.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Geriatrics, Hôpital Broca, Rue Pascal, Paris, France

    O Hanon, M-L Seux, H Lenoir, A-S Rigaud & F Forette

  2. Department of Endocrinology—Cardiovascular Prevention Unit, Hôpital de la Pitié Salpêtrière, Paris, France

    X Girerd

Authors
  1. O Hanon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M-L Seux
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Lenoir
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A-S Rigaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. X Girerd
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F Forette
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O Hanon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hanon, O., Seux, ML., Lenoir, H. et al. Diuretics for cardiovascular prevention in the elderly. J Hum Hypertens 18 (Suppl 2), S15–S22 (2004). https://doi.org/10.1038/sj.jhh.1001796

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001796

Keywords

This article is cited by

Search

Advanced search

Quick links